Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 21, 2019

View Archived Issues

Ebola antibody cocktail is drug development model

In immunotherapy, translation's translational potential

Anxiety affects weight via BDNF, inhibitory neurons

Enrollment ongoing in phase I study of MRX-0518 plus pembrolizumab in patients with solid tumors

FDA accepts IND application for phase I/II study of AVR-RD-04 gene therapy for cystinosis

Fat and happy: combination treatment subverts tumor cell plasticity

OliX nominates OLX-10020 as a clinical candidate for geographic atrophy

Celgene enters two cancer immunotherapy collaborations

Xiamen University divulges RET inhibitors

Selvita presents adenosine A2A receptor antagonists

Aradigm releases third-party evaluation results of Apulmiq phase III trials

Preliminary phase Ib data presented for GLS-010 in patients with advanced gastrointestinal tumors

Phase I results reported for galunisertib plus SBRT in advanced hepatocellular carcinoma

Canerpaturev plus standard chemotherapy shows encouraging antitumor activity in pancreatic cancer

Phase III ANNOUNCE study of Lartruvo in soft tissue sarcoma does not meet primary endpoints

Phase III RESOLVE trial of ibrutinib in metastatic pancreatic cancer misses primary endpoint

Gilead presents phase III data for andecaliximab combined with chemotherapy

FDA approves trastuzumab biosimilar Ontruzant

Redx receives MHRA clearance to resume RXC-004 clinical trial program

First-in-human study evaluates EMB-01 in advanced/metastatic solid tumors

Syntrix opens enrollment for phase I study of SX-682 in metastatic melanoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...